Optimizing treatment of diabetes and cardiovascular disease with combined α,β-blockade

Current Medical Research and Opinion

Volumn 21, Issue 8, 2005, Pages 1191-1200

  Bell, David S H ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

Blockers; Cardiovascular disease; Carvedilol; Diabetes

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; CHLORTALIDONE; DILEVALOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INSULIN; LABETALOL; LOSARTAN; METOPROLOL; PINDOLOL; PROPRANOLOL; SULFONYLUREA; THIAZIDE DIURETIC AGENT; TIMOLOL;

CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; REVIEW;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; HUMANS; INSULIN RESISTANCE; RISK FACTORS;

EID: 23744484954     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X53306     Document Type: Review

References (95)

1. Dornhorst A, Powell SH, Pensky J. Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion. Lancet 1985;1:123-6
2. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-9
3. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-94
4. Haas SJ, Vos T, Gilbert RE, Krum H. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146:848-53
5. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The national health and nutrition examination surveys, 1960 to 1991. J Am Med Assoc 1994;272:205-11
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 1979;241:2035-8
7. Colagiuri S, Cull CA, Holman RR. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61. Diabetes Care 2002;25:1410-7
8. Celentano A, Vaccaro O, Tammaro P, et al. Early abnormalities of cardiac function in non-insulin-dependent diabetes mellitus and impaired glucose tolerance. Am J Cardiol 1995;76:1173-6
9. Cress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities study. New Engl J Med 2000;342:905-12
10. Harris MI. Epidemiology of diabetes mellitus among the elderly in the United States. Clin Geriatr Med 1990;6:703-19
11. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229-34
12. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Br Med J 2002;324:939
13. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. J Am Med Assoc 2001;285:2486-97
14. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure]. J Am Coll Cardiol 2001;38:2101-13
15. Bloomgarden ZT. Obesity, hypertension, and insulin resistance. Diabetes Care 2002;25:2088-97
16. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. New Engl J Med 2004;350:664-71
17. Patti ME, Butte AJ, Crunkhorn S, et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 2003;100:8466-71
18. Zavaroni I, Mazza S, Dall'Aglio E, et al. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992;231:235-40
19. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997;30:527-32
20. Bell DS. Diabetic cardiomyopathy. Diabetes Care 2003;26:2949-51
21. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med 1984;311:819-23
22. Goldstein DS. Plasma catecholamines and essential hypertension. An analytical review. Hypertension 1983;5:86-99
23. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258-65
24. Packer M. Beta-adrenergic blockade in chronic heart failure: principles, progress, and practice. Prog Cardiovasc Dis 1998;41:39-52
25. Coats AJ, Anker SD, Anker S. Insulin resistance in chronic heart failure. J Cardiovasc Pharmacol 2000;35:S9-S14
26. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New Engl J Med 1988;318:1315-21
27. Bell DSH. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care 1995;18:708-14
28. Ziegelhoffer A, Ravingerova T, Styk J, et al. Mechanisms that may be involved in calcium tolerance of the diabetic heart. Mol Cell Biochem 1997;176:191-8
29. Wakasaki H, Koya D, Schoen FJ, et al. Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 1997;94:9320-5
30. Szabo C. PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Perspect 2002;15:197-205
31. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 2002;105:1861-70
32. Stahl A, Evans JG, Pattel S, Hirsch D, Lodish HF. Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev Cell 2002;2:477-88
33. Meijssen S, Cabezas MC, Ballieux CG, et al. Insulin mediated inhibition of hormone sensitive lipase activity in vivo in relation to endogenous catecholamines in healthy subjects. J Clin Endocrinol Metab 2001;86:4193-7
34. Morimoto C, Tsujita T, Okuda H. Norepinephrine-induced lipolysis in rat fat cells from visceral and subcutaneous sites: role of hormone-sensitive lipase and lipid droplets. J Lipid Res 1997;38:132-8
35. Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993;33:286-91
36. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607
37. Ridker PM, Genest J, Libby P. Risk factors for atherosclerotic disease. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease: a textbook of cardiovascular medicine. Philadelphia: Saunders; 2001. p. 1010-40
38. Shen GX, Cai W, Angel A. Increased secretion of cholesteryl ester transfer protein from hamster adipose tissue: stimulation by beta-adrenergic agents. Atherosclerosis 1998;140:113-20
39. Bowie A, Owens D, Collins P, Johnson A, Tomkin GH. Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 1993;102:63-7
40. Knott HM, Brown BE, Davies MJ, Dean RT. Glycation and glycoxidation of low-density lipoproteins by glucose and low-molecular mass aldehydes. Formation of modified and oxidized particles. Eur J Biochem 2003;270:3572-82
41. Oliver MF, Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. Lancet 1994;343:155-8
42. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. J Am Med Assoc 2003;289:2560-72
43. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6
44. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [Committee on Management of Acute Myocardial Infarction]. Circulation 1999;100:1016-30
45. Smith Jr SC, Blair SN, Bonow RO, et al. AHA/ACC scientific statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-9
46. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
47. MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7
48. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med 2001;344:1651-8
49. Tse WY, Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients? Diabet Med 1994;11:137-44
50. Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 2004;93:49-52
51. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713-20
52. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998;351:1755-62
53. Kjekshus J, Gilpin E, Cali G, et al. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43-50
54. Gundersen T, Kjekshus J. Timolol treatment after myocardial infarction in diabetic patients. Diabetes Care 1983;6:285-90
55. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. New Engl J Med 1998;339:489-97
56. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease [Bezafibrate Infarction Prevention (BIP) Study Group]. Am J Cardiol 1996;77:1273-7
57. Fonarow GC. The acute decompensated heart failure national registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003;4(Suppl 7):S21-S30
58. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38
59. Rocha RM, Silva GV, Perin EC, et al. Effects of carvedilol therapy on QT-interval dispersion in congestive heart failure: is there a difference in the elderly? Tex Heart Inst J 2003;30:176-9
60. Mohacsi P, Fowler MB, Krum H, et al. Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes? Results of the COPERNICUS study. Presented at the American Heart Association 74th Annual scientific Session; November 14, 2001; Anaheim, CA [abstract 3551]. Circulation 2001;104(Suppl II):II-754
61. Bristow MR. Effect of carvedilol on LV function and mortality in diabetic vs non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Presented at the 69th Scientific Sessions, New Orleans Convention Center; November 10-13, 1996; New Orleans, LA. Circulation 1996;84:I-644
62. Fonarow GC. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 2004;116(Suppl 5A):76S-88S
63. Black HR. Metabolic considerations in the choice of therapy for the patient with hypertension. Am Heart J 1991;121:707-15
64. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-38
65. Barzilay JI, Pressel S, Davis BR, et al. Risk and impact of incident glucose disorders in hypertensive older adults treated with an ACE inhibitor, a diuretic, or a calcium channel blocker: a report from the ALLHAT trial. Am J Hypertens 2004;17:S1
66. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 2002;288:2981-97
67. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the losartan intervention for endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86
68. Olsen MH, Possum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005;23:891-8
69. Torp-Pedersen C, Cleland JG, Metra M, et al. Effect of long-term treatment with carvedilol compared to metoprolol on heart failure morbidity and diabetes in COMET. Presented at the American College of Cardiology (ACC) 53rd Annual Scientific Sessions; March 7-10, 2004; New Orleans, LA; Tracking number - 04-A-294565-ACC. J Am Coll Cardiol 2004;43
70. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. New Engl J Med 1996;334:374-81
71. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New Engl J Med 1981;304:801-7
72. Weinberger MH. Antihypertensive therapy and lipids. Evidence, mechanisms, and implications. Arch Intern Med 1985;145:1102-5
73. Osmundson PJ, O'Fallon WM, Zimmerman BR, et al. Course of peripheral occlusive arterial disease in diabetes. Vascular laboratory assessment. Diabetes Care 1990;13:143-52
74. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2:650-3
75. Schaper NC, Nabuurs-Franssen MH, Huijberts MS. Peripheral vascular disease and type 2 diabetes mellitus. Diabetes Metab Res Rev 2000;16(Suppl 1):S11-S15
76. International Working Group on the Diabetic Foot. Peripheral vascular disease. In: Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC, editors. International consensus on the diabetic foot. Maastricht: International Diabetes Federation; 1999. p. 33-41
77. Beach KW, Bedford GR, Bergelin RO, et al. Progression of lower-extremity arterial occlusive disease in type II diabetes mellitus. Diabetes Care 1988;11:464-72
78. Popp DA, Tse TF, Shah SD, Clutter WE, Cryer PE. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. Diabetes Care 1984;7:243-7
79. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. J Am Med Assoc 1997;278:40-3
80. Deacon SP, Karunanayake A, Barnett D. Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetics. Br Med J 1977;2:1255-7
81. Bell DSH, Yumuk V. Frequency of severe hypoglycemia in patients with non-insulin-dependent diabetes mellitus treated with sulfonylureas or insulin. Endocr Pract 1997;3:281-3
82. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;198:1152-7
83. Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens 1994;8:257-63
84. Leren P, Foss PO, Helgeland A, et al. Effect of propranolol and prazosin on blood lipids [The Oslo Study]. Lancet 1980;2:4-6
85. Haenni A, Lithell H. Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455-61
86. FDA Working Group, Pharmaceutical Research Manufacturers of America, American Association for the Study of Liver Diseases. Clinical white paper. Prepared for the conference, drug-induced liver injury: a national and global problem, 12-13 February 2001, Westfields Conference Center, Chantilly, VA. 2000
87. Malminiemi K. Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Ther 1995;9:295-304
88. Flamenbaum W, Weber MA, McMahon FG, et al. Monotherapy with labetalol compared with propranolol. Differential effects by race. J Clin Hypertens 1985;1:56-69
89. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. J Am Med Assoc 2004;292:2227-36
90. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12
91. Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC- Norfolk). Br Med J 2001;322:15-8
92. Barzilay JI, Peterson D, Cushman M, et al. The relationship of cardiovascular risk factors to microalbuminuria in older adults with or without diabetes mellitus or hypertension: the cardiovascular health study. Am J Kidney Dis 2004;44:25-34
93. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-7
94. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001;286:421-6
95. Messerli F, Bakris G, Bell D, et al. Weight change and insulin sensitivity - not all beta-blockers are created equal. Presented at: American Society of Hypertension 20th Annual Scientific Meeting and Exposition; May 14-18 2005; San Francisco, CA